User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Reversion of resistance in relapsing infection caused by a glycopeptide-intermediate methicillin-resistant Staphylococcus aureus isolate.

  1. Ruef C (2004) Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 32:315–327
  2. Nonhoff C, Denis O, Struelens MJ (2005) Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals. Clin Microbiol Infect 11:214–220
  3. Clinical and Laboratory Standards Institute (2006) Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. Approved standard MS100-S16. CLSI (formerly NCCLS), Wayne, PA
  4. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D (2001) Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39:2439–2444
  5. Harmsen D, Claus H, Witte W, Rothganger J, Claus H, Turnwald D, Vogel U (2003) Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 41:5442–5448
  6. Denis O, Deplano A, Nonhoff C, Hallin M, De Ryck R, Vanhoof R, De Mendonca R, Struelens MJ (2006) In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother 50:2680–2685
  7. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A (2003) Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol 41:1687–1693
  8. Boyle-Vavra S, Berke SK, Lee JC, Daum RS (2000) Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 44:272–277
  9. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, Tenover FC, Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group (2003) Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997–2001. Clin Infect Dis 36:429–439
  10. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering Jr RC, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402
  11. Goldstein FW, Kitzis MD (2003) Vancomycin-resistant Staphylococcus aureus: no apocalypse now. Clin Microbiol Infect 9:761–765
Bibliographic reference Huang, Te-Din ; Almpanis, C ; Denis, O. ; Nonhoff, C. ; Delaere, Bénédicte ; et. al. Reversion of resistance in relapsing infection caused by a glycopeptide-intermediate methicillin-resistant Staphylococcus aureus isolate.. In: European journal of clinical microbiology & infectious diseases, Vol. 26, no. 6, p. 419-422 (2007)
Permanent URL